# OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC

> **NCT03806309** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GERCOR - Multidisciplinary Oncology Cooperative Group** · enrollment: 106 (estimated)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma
- Locally Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** FOLFIRI
- **DRUG:** OSE2101

## Key facts

- **NCT ID:** NCT03806309
- **Lead sponsor:** GERCOR - Multidisciplinary Oncology Cooperative Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-10
- **Primary completion:** 2024-12-09
- **Final completion:** 2025-12
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806309, "OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03806309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*